{"prompt": "['Trelagliptin-4002', 'Page 21 of 66', 'Version 1.0', 'November 2, 2016', 'Changes in the score per question in the DTSQ at each assessment time point.', '5.2.2.2 Safety endpoints', 'Adverse events', 'Incidence of hypoglycemia', 'Hospitalization for type 2 diabetes (duration and number, excluding educational', 'hospitalization without worsening of diabetes)', '5.2.3 Other Enppoints', 'Laboratory tests [HbA1c, fasting blood glucose, fasting insulin, fasting glucagon, glycoalbumin,', '1,5-AG, serum creatinine, urinary 8-OHdG (using a correction value of uric creatinine', '(8-OHdG/creatinine)) and urinary creatinine]', 'Treatment compliance', 'The Basic Information on Study Subject (Your Basic Profile)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 22 of 66', 'Version 1.0', 'November 2, 2016', '6.0', 'CLINICAL STUDY DESIGN', '6.1', 'Clinical study design', '<Clinical study design>', 'This is a multi-center, randomized, open-label, parallel-group comparison study to assess the', 'reduction in treatment burden during the administration of a DPP-4 inhibitor (trelagliptin or a daily', 'DPP-4 inhibitor) for 12 weeks in patients with type 2 diabetes on diet and exercise therapy only.', 'Eligible study subjects as a result of eligibility assessment after giving informed consent will be', 'randomized to either of the study drug (trelagliptin) group or the comparative drug (daily DPP-4', 'inhibitor) group as specified in Section 8.4.', '< Dosage and Administration>', 'The study drug group: Trelagliptin 100 mg is orally administered once weekly. Trelagliptin 50', 'mg is orally administered once weekly in patients with moderate renal', 'impairment.', 'The comparative drug group: An inhibitor is orally administered at the dosage and administration in', 'the package inserts for each drug.', '<Evaluation period and visit frequency for study subjects>', 'Evaluation period: 16 weeks (Screening period: 4 weeks; treatment period: 12 weeks)', 'Number of visits: total 4 visits', 'A study subject will visit to his/her study site at the start of the screening period (Visit 1;', 'Week -4), at the start of the treatment period (Visit 2; Week 0 of the treatment period),', 'during the treatment period (Visit 3; Week 4 of the treatment period) and at the end of', 'the treatment period (Visit 4; Week 12 of the treatment period).', '<Planned number of study subjects>', 'As the number of randomized subjects:', 'The study drug (Trelagliptin) group 120 subjects', 'The comparative drug (daily DPP-4 inhibitor) group 120 subjects', '<Number of study sites>', 'Approximately 15', 'Figure 6 (a) shows an outline of the clinical study design. Refer to Appendix A for schedule of', 'examinations, observations, and evaluations.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 23 of 66', 'Version 1.0', 'November 2, 2016', 'Start of study', 'Informed consent procedure', 'drug', 'Eligibility tests', 'administration', 'Visit', '1', '2', '3', '4', 'Week', '-4', '0', '4', '12', 'Time window', '-29 to -1', '0', '21 to 35', '70 to 97', 'Screening period', 'Treatment', 'The study drug (Trelagliptin)', 'Trelaglipin 100 mgor50 mg/week', 'group', 'On diet and exercise therapy only', 'The comparative drug (Daily', 'Daily DPP-4inhibitor', 'DPP-4inhibitor) group', '4', '+', 'DTR-QOL', 'DTR-QOL', 'DTR-QOL', 'DTR-QOL', 'DTSQ', 'DTSQ', 'DTSQ', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}